Stryker Q3 - Returned To Growth

Stryker released its earnings last week Thursday at the same time as all our big technology holdings, I'm happy to be finally getting around to writing about this amazing business. In the last set of results, this business was hurt a lot by a decline in elective surgeries in order to enforce social contact restrictions as a response to the Covid-19 pandemic.

These recent results showed that Stryker returned back to growth in the third-quarter with revenues up 4.2% to $3.74 billion and earnings per share up 12% of $2.14 both beating market expectations. This is thanks to local governments and healthcare authorities slowly reversing their deferral of elective surgeries as things start to normalise. Yes, people can go for their rhinoplasty surgery in peace again.

All three segments of the business i.e. Orthopaedics, MedSurg, 'Neurotechnology and Spine' did well with net sales growing by 4.4%, 3.2%, and 6% respectively thanks to increased unit volumes and Wright Medical integration. These results were achieved while the business and the world are both still recovering from the impact of the Covid-19 pandemic.

People like Paul can be more active without having to worry about busting their knees and hips because they know companies like Stryker are there to help them in case of a worst-case scenario with a fresh new replacement. Stryker remains our preferred holding in the Medtech space and the medical community loves their brands. Get some shares on this temporary dip!